Design and synthesis of amino-substituted N-arylpiperidinyl-based inhibitors of the (immuno)proteasome by Gobec Martina, Obreza Aleš, Jukič Marko, Baumgartner Ana, Mihelčič Nja, Potočnik Špela, Virant Julija, Mlinarič Irena, Stanislav Raščan, Sosič Gobec Izidor

Subjects: “…proteasomes…”
Get full text

Structural comparison of human and Plasmodium proteasome β5 subunits: informing selective inhibitor design for anti-malaria agents by Muhammad Yasir, Jinyoung Park, Eun-Taek Han, Won Sun Park, Jin-Hee Han, Wanjoo Chun

Subjects: Get full text

Molecular insights into the unique properties of the blood‐circulating proteasome by Yegor Leushkin, David Morgenstern, Shifra Ben‐Dor, Rebecca Haffner‐Krausz, Katharina Zittlau, Gili Ben‐Nissan, Michal Sharon

Subjects: Get full text

Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients by Eva Plakoula, Georgios Kalampounias, Spyridon Alexis, Evgenia Verigou, Alexandra Kourakli, Kalliopi Zafeiropoulou, Argiris Symeonidis

Subjects: Get full text

Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects by Ada Alice Dona, Theophilus Tandoh, Lokesh Nigam, Mahmoud Singer, Enrico Caserta, Mariam Murtadha, Yinghui Zhu, Milad Moloudizargari, Preeti Sharma, Ottavio Napolitano, Janet Winchester, Arnab Chowdhury, Alex Pozhitkov, James F. Sanchez, Hawa Vahed, Guido Marcucci, Matt Coffey, Gerard Nuovo, Douglas W. Sborov, Flavia Pichiorri, Craig C Hofmeister

Subjects: “…Proteasome inhibitors…”
Get full text

Mechanisms of ubiquitin-independent proteasomal degradation and their roles in age-related neurodegenerative disease by Taylor R. Church, Seth S. Margolis, Seth S. Margolis

Subjects: Get full text

USP14 is crucial for proteostasis regulation and α-synuclein degradation in human SH-SY5Y dopaminergic cells by Vignesh Srinivasan, Rabah Soliymani, Larisa Ivanova, Ove Eriksson, Nina Peitsaro, Maciej Lalowski, Mati Karelson, Dan Lindholm

Subjects: Get full text

Enhancing proteasome activity by NMDAR antagonists explains their therapeutic effect in neurodegenerative and mental diseases by Fikret Sahin, Aslihan Gunel, Buse Turegun Atasoy, Ulku Guler, Bekir Salih, Isinsu Kuzu, Mehmet Taspinar, Ozgur Cinar, Selda Kahveci

Subjects: Get full text

CCL5 Induces a Sarcopenic-like Phenotype via the CCR5 Receptor by Francisco Aguirre, Franco Tacchi, Mayalen Valero-Breton, Josué Orozco-Aguilar, Sabrina Conejeros-Lillo, Josefa Bonicioli, Renata Iturriaga-Jofré, Daniel Cabrera, Jorge A. Soto, Mauricio Castro-Sepúlveda, Marianny Portal-Rodríguez, Álvaro A. Elorza, Andrea Matamoros, Felipe Simon, Claudio Cabello-Verrugio

Subjects: Get full text

Oversized cells activate global proteasome-mediated protein degradation to maintain cell size homeostasis by Shixuan Liu, Ceryl Tan, Chloe Melo-Gavin, Miriam B Ginzberg, Ron Blutrich, Nish Patel, Michael Rape, Kevin G Mark, Ran Kafri

Subjects: Get full text

Identification of MORF4L1 as an endogenous substrate of CRBN and its potential role as a therapeutic target in cancer by Luyao Zhang, Shunfang Liu, Jingliang He, Zhongke Hu, Lan Zhu, Hongyi Huang, Qi Gao, Dan Wang, Lu Chen, Xingyu Zhang, Ruotong Liu, Jiayun Wang, Yizhuo Song, Kaile Zeng, Xiuming Li, Yulu Chen, Xun Zou, Shaojie Ma, Xiujun Wang, Guofeng Xu, Wei Liu, Bin Liu

Subjects: Get full text

Rational design of novel phenol ether derivatives as non-covalent proteasome inhibitors through 3D-QSAR, molecular docking and ADMET prediction by Miao Yuan, Hanwen Ji, Fengxin Sun, Qiang Chen, Ping Cheng

Subjects: “…non-covalent proteasome inhibitor…”
Get full text